263 related articles for article (PubMed ID: 22644035)
21. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
22. Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon.
Ragupathy V; Zhao J; Wood O; Tang S; Lee S; Nyambi P; Hewlett I
Virol J; 2011 Apr; 8():185. PubMed ID: 21513545
[TBL] [Abstract][Full Text] [Related]
23. Effects of human immunodeficiency virus type 1 transframe protein p6* mutations on viral protease-mediated Gag processing.
Chiu HC; Wang FD; Chen YA; Wang CT
J Gen Virol; 2006 Jul; 87(Pt 7):2041-2046. PubMed ID: 16760407
[TBL] [Abstract][Full Text] [Related]
24. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
Shibata J; Sugiura W; Ode H; Iwatani Y; Sato H; Tsang H; Matsuda M; Hasegawa N; Ren F; Tanaka H
Antiviral Res; 2011 Apr; 90(1):33-41. PubMed ID: 21338625
[TBL] [Abstract][Full Text] [Related]
25. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
26. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?
de Oliveira T; Engelbrecht S; Janse van Rensburg E; Gordon M; Bishop K; zur Megede J; Barnett SW; Cassol S
J Virol; 2003 Sep; 77(17):9422-30. PubMed ID: 12915557
[TBL] [Abstract][Full Text] [Related]
27. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
[TBL] [Abstract][Full Text] [Related]
29. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
30.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
31. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
[TBL] [Abstract][Full Text] [Related]
32. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
[TBL] [Abstract][Full Text] [Related]
33. The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.
Knops E; Kemper I; Schülter E; Pfister H; Kaiser R; Verheyen J
AIDS; 2010 Mar; 24(5):779-81. PubMed ID: 20139751
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 protease with leucine zipper fused at N-terminus exhibits enhanced linker amino acid-dependent activity.
Yu FH; Wang CT
Retrovirology; 2018 Apr; 15(1):32. PubMed ID: 29655366
[TBL] [Abstract][Full Text] [Related]
35. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
[TBL] [Abstract][Full Text] [Related]
36. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
37. Short communication: high natural polymorphism in the gag gene cleavage sites of non-B HIV type 1 isolates from Gabon.
Liégeois F; Reteno DG; Mouinga-Ondémé A; Sica J; Rouet F
AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1179-82. PubMed ID: 23551028
[TBL] [Abstract][Full Text] [Related]
38. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
[TBL] [Abstract][Full Text] [Related]
39. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
40. Genotypic prediction of resistant mutation in HIV-1 pol gene towards the antiretroviral drugs.
Kumar A; Jadhav C
Int J Bioinform Res Appl; 2011; 7(1):15-23. PubMed ID: 21441094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
